Xbrane Biopharma Q2 2024: A fight against the clock - Redeye

Redeye updates its view on Xbrane following a Q2 report hinting at accelerating sales but also highlighting a vulnerable financial position. We adjust our fair value range to reflect the financing situation and the loss of Biogen as a partner in the XBR003 (BIIB801) project.

Länk till analysen i sin helhet: https://www.redeye.se/research/1037184/xbrane-biopharma-q2-2024-a-fight-against-the-clock?utm_source=finwire&utm_medium=RSS